TheraRadar

Angiotensin 2 Receptor Blocker

Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.

View Angiotensin 2 Receptor Blocker patent landscape →
LOE waterfall across 4 approved drugs, patent families, sponsor concentration, country footprint
17
Approved drugs
33
Active Phase 3
8
Indications tested
7
Active sponsors

17 FDA-approved Angiotensin 2 Receptor Blocker drugs, including AVAPRO, with 33 active Phase 3 trials across 8 indications from 7 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.

Approved Angiotensin 2 Receptor Blocker Drugs

17 total

Angiotensin 2 Receptor Blocker Indications in Trials

Active industry trials

Active industry trials by indication. Click to see the full pipeline.

Immunoglobulin A Nephropathy
1 sponsor
P3 1
Essential Hypertension
1 sponsor
P3 1
Mild-to-moderate Essential Hypertension
1 sponsor
P3 1
Focal Segmental Glomerulosclerosis
1 sponsor
P2 1
Minimal Change Disease
1 sponsor
P2 1
Chronic Kidney Disease
1 sponsor
P2 1
Immunoglobulin a Nephropathy
1 sponsor
P2 1
Proteinuria
1 sponsor

Top Angiotensin 2 Receptor Blocker Sponsors

Industry trials, any indication

Companies with active industry trials in this mechanism.

Travere Therapeutics, Inc.
P3 1 3 total
Chong Kun Dang Pharmaceutical
P3 1 2 total
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P3 1 1 total
Shenzhen Ausa Pharmed Co.,Ltd
2 total
Jiangsu Hansoh Pharmaceutical Co., Ltd.
1 total
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
1 total
Hansoh BioMedical R&D Company
1 total

Methodology

Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.

"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.